Latest Cambridge Antibody Technology Stories
COPENHAGEN and OSLO, March 4 /PRNewswire/ -- Pharmexa A/S and Affitech AS announced today that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS.
- Delivery of 20,000 doses of ABthrax will bring at least $150 million in revenue to HGS - ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr.
GAITHERSBURG, Md., Nov. 13 /PRNewswire/ -- MedImmune today announced the appointment of Tony Zook as its president. Previously, he had been heading the company on an interim basis. MedImmune is the wholly owned biologics business for AstraZeneca PLC. In addition to MedImmune, Mr.
Genaera, a biopharmaceutical company, has reported that its development partner MedImmune presented interim Phase IIa data on MEDI-528, its monoclonal antibody targeting interleukin-9 in adults with mild, persistent asthma.
BERKELEY, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Stephen K. Doberstein, Ph.D., to the position of Vice President of Research. In this position, Dr.
OSLO, Norway, October 28 /PRNewswire/ -- Affitech AS, the human therapeutic antibody company, today announced that it had acquired the full rights to the innovative diabody technology originally owned by Pharmexa A/S, a leading Danish immunotherapeutic and vaccine company.
BERKELEY, Calif., Oct. 25, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd.
ImmunoCellular Therapeutics, a biotechnology company, has received two separate US patents relating to the company's monoclonal antibody therapeutics.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, announced the issuance of two separate U.S. patents relating to the company's monoclonal antibody therapeutics. Patents No. 7,435,415 and No.